Some, do what it says on the tin.
Some...not so much.
The issue with any new chemical is full, comprehensive, regulated testing.
Dodgy folks aren't really so good, with that last part. They use their customers as guinea pigs.
Since sequential steps are slow, I think we're going to see massive increases in parallelization. I'm not sure how the regulatory frameworks will keep up honestly.
Why? This is not an AI problem, it's an industry one. And if it was simple, it would already exist.
Not necessarily. Many things are simply gatekept behind the door.
I wonder what the unlock would be, if any, of having simulations substitute any (or all, in time) of these steps. Akin to the method used to train FSD cars, or robots.-
“Generate scientist” … is that a real job like “prompt engineer”
Same applies to construction projects, BTW.
adamredwoods•49m ago
>> If Claude is to significantly increase the rate of new cures, we need to work with many more biotechnology firms and integrate Claude more deeply into their development processes
Sounds invasive.
dyauspitr•27m ago